Fosfomycin as Oral Transition Therapy Versus Continued Intravenous β-Lactams for Complicated Urinary Tract Infections Caused by Extended-Spectrum β-Lactamase–Producing Enterobacterales : A Multicenter, Open-Label, Randomized Controlled Trial
Clinical Infectious Diseases · 2026
DOI: 10.1093/cid/ciag345 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical Infectious Diseases, 2026. Verfasst von Jun-Won Seo und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, College of Medicine, Chosun University, Gwangju Metropolitan City, Republic of Korea. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, beta-Lactams, Enterobacteriaceae Infections, Fosfomycin. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: National Institute of Infectious Diseases.
Abstract (Originalsprache)
Background
Extended-spectrum β-lactamase (ESBL)–producing Enterobacterales are an increasing cause of complicated urinary tract infections (UTIs). Reliance on carbapenems to treat these infections accelerates resistance, underscoring the urgent need for effective oral transition options to preserve last-line agents and lessen healthcare burden.
Methods
We conducted a multicenter, open-label, randomized, noninferiority trial at four tertiary hospitals in South Korea (November 2022–June 2025). Adults hospitalized with complicated UTIs due to ESBL-producing Enterobacterales who improved after 3–7 days of intravenous antibiotics were randomized (1:1) to either continue intravenous carbapenem or β-lactam/β-lactamase inhibitor therapy or switch to oral fosfomycin trometamol (3 g once daily). The primary outcome was clinical cure, defined as resolution of urinary tract infection–related symptoms and signs within 4 days after completion of treatment. Secondary outcomes included microbiological cure, readmission, adverse events, and 30-day recurrence.
Results
Of the 344 screened patients, 299 were randomized (152 oral fosfomycin; 147 intravenous therapy). Clinical cure occurred in 92.8% of the oral fosfomycin group and 95.2% of the intravenous group (risk difference, −2.47%; 95% CI −7.84 to 2.89), confirming noninferiority. Microbiological cure was similarly high in both groups: urine (98.0% vs 96.6%) and blood (97.3% vs 97.5%). Safety profiles and 30-day outcomes were also comparable.
Conclusions
Oral fosfomycin was noninferior to continued intravenous therapy when used as oral transition therapy for complicated UTIs caused by ESBL-producing Enterobacterales. These findings provide evidence to support oral fosfomycin transition as a carbapenem-sparing antibiotic stewardship strategy for patients with complicated UTIs caused by ESBL-producing Enterobacterales. Clinical Trials Registration KCT0007669.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, College of Medicine, Chosun University, Gwangju Metropolitan City, Republic of Korea.
- Department of Urology, Chosun University College of Medicine, Gwangju Metropolitan City, Republic of Korea.
- Division of Infectious Diseases, Department of Internal Medicine, Ewha Womans University, Mokdong Hospital, Seoul, Republic of Korea.
- Division of Infectious Diseases, Department of Internal Medicine, Yeungnam University Medical Center, Daegu Metropolitan City, Republic of Korea.
- Division of Infectious Diseases, Department of Internal Medicine, Yongin Severance Hospital, Yonsei University College of Medicine, Gyeonggi-do, Republic of Korea.
- Department of Laboratory Medicine, Yongin Severance Hospital, Yonsei University College of Medicine, Gyeonggi-do, Republic of Korea.
ORCID-Profile: Jun-Won Seo, Da Young Kim, Youngmin Yoon, Young Sang Lyu, Yong Sub Na, Do Sik Moon, Na Ra Yun, Min Seok Kim, Sang Woon Bae, Jian Hur, Min Hyung Kim, Yoon Soo Park, Heejung Kim, Hyungdon Lee, Younggwon On, Seok Hyeon Na, Hee-Chang Jang, Dong-Min Kim
Förderung
- National Institute of Infectious Diseases
Zitieren
APA
Seo, J. W., Kim, D. Y., Yoon, Y., Lyu, Y. S., Na, Y. S., Moon, D. S., Yun, N. R., Kim, M. S., Kim, J. H., Bae, S. W., Hur, J., Kim, M. H., Park, Y. S., Kim, H., Lee, H., On, Y., Na, S. H., Yoo, J. S., Jang, H. C., & Kim, D. M. (2026). Fosfomycin as Oral Transition Therapy Versus Continued Intravenous β-Lactams for Complicated Urinary Tract Infections Caused by Extended-Spectrum β-Lactamase–Producing Enterobacterales : A Multicenter, Open-Label, Randomized Controlled Trial. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciag345
Vancouver
Seo JW, Kim DY, Yoon Y, Lyu YS, Na YS, Moon DS, et al. Fosfomycin as Oral Transition Therapy Versus Continued Intravenous β-Lactams for Complicated Urinary Tract Infections Caused by Extended-Spectrum β-Lactamase–Producing Enterobacterales : A Multicenter, Open-Label, Randomized Controlled Trial. Clinical Infectious Diseases. 2026. doi:10.1093/cid/ciag345
BibTeX
@article{Seo2026,
author = {Seo, Jun-Won and Kim, Da Young and Yoon, Youngmin and Lyu, Young Sang and Na, Yong Sub and Moon, Do Sik and Yun, Na Ra and Kim, Min Seok and Kim, Jeong-Han and Bae, Sang Woon and Hur, Jian and Kim, Min Hyung and Park, Yoon Soo and Kim, Heejung and Lee, Hyungdon and On, Younggwon and Na, Seok Hyeon and Yoo, Jung Sik and Jang, Hee-Chang and Kim, Dong-Min},
title = {Fosfomycin as Oral Transition Therapy Versus Continued Intravenous β-Lactams for Complicated Urinary Tract Infections Caused by Extended-Spectrum β-Lactamase–Producing Enterobacterales : A Multicenter, Open-Label, Randomized Controlled Trial},
journal = {Clinical Infectious Diseases},
year = {2026},
doi = {10.1093/cid/ciag345}
}
EUVIMED